Avet Pharma Announces Leadership Transition: CEO George Svokos to Retire

Avet Pharma announced that President and Chief Executive Officer George Svokos will retire effective April 3, 2026. Svokos, who guided the company through a successful multi-year turnaround and operational strengthening, will continue to serve Avet as a member of the Board of Directors. Avet is also pleased to announce the promotion of Dan Lukasiewicz to Chief Commercial Officer (CCO).

In this elevated role, Lukasiewicz will assume full responsibility for Avet's commercial strategy, including sales, marketing, and business development. He has been instrumental in the company's recent growth and the modernization of its commercial infrastructure. "Dan's deep institutional knowledge, coupled with his proven track record of driving revenue and building high-performing teams, makes him the natural choice to lead our commercial organization," said Vikas Thapar, Chairman of the Board.

Reflecting on the appointment, Lukasiewicz stated: "I am honored to lead our commercial organization at such a pivotal moment. I am fully committed to accelerating our momentum. Our focus is clear: we will continue to be a reliable, agile partner to our customers while aggressively expanding our portfolio and market presence."

Avet Pharma extends its deepest gratitude to George Svokos for his leadership and looks forward to a seamless transition as it continues to execute its strategic priorities.